Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) Debt to Equity (2019 - 2025)

Harmony Biosciences Holdings' Debt to Equity history spans 7 years, with the latest figure at $0.19 for Q4 2025.

  • For Q4 2025, Debt to Equity fell 30.85% year-over-year to $0.19; the TTM value through Dec 2025 reached $0.19, down 30.85%, while the annual FY2025 figure was $0.19, 30.85% down from the prior year.
  • Debt to Equity for Q4 2025 was $0.19 at Harmony Biosciences Holdings, down from $0.2 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.81 in Q1 2021 and bottomed at $0.19 in Q4 2025.
  • The 5-year median for Debt to Equity is $0.41 (2023), against an average of $0.61.
  • The largest annual shift saw Debt to Equity crashed 55.87% in 2022 before it dropped 12.3% in 2024.
  • A 5-year view of Debt to Equity shows it stood at $1.03 in 2021, then crashed by 53.78% to $0.48 in 2022, then dropped by 12.87% to $0.41 in 2023, then plummeted by 34.39% to $0.27 in 2024, then plummeted by 30.85% to $0.19 in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Debt to Equity are $0.19 (Q4 2025), $0.2 (Q3 2025), and $0.22 (Q2 2025).